Skip to main content
Fig. 1 | Journal of Neuroinflammation

Fig. 1

From: Superior control of inflammatory pain by corticotropin-releasing factor receptor 1 via opioid peptides in distinct pain-relevant brain areas

Fig. 1

Antagonism of antinociceptive effects of i.c.v. administered CRF by CRF-R1 antagonist NBI 27914 and CRF-R2 antagonist K41498. In Wistar rats with 4-day FCA-induced hind paw inflammation, effects of i.c.v. administered CRF on nociceptive paw pressure thresholds were measured by algesiometry. A i.c.v. application of CRF (0.5, 01.0, 1.5, 2.0 µmol) significantly increased nociceptive thresholds in a dose-dependent manner (F(4, 25) = 445; P < 0.001). B Dose-dependent antagonism of i.c.v. CRF’s antinociception by co-administered CRF-R1 antagonist NBI 27914 (F(4, 25) = 502.9; P < 0.001). C In contrast, increasing doses of the i.c.v. CRF-R2 antagonist K41498 only partially antagonized CRF’s antinociception (F(4, 25) = 315.7; P < 0.001). *indicates significant differences from vehicle treatment; data points (n = 6) represent means ± SD

Back to article page